Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
Do you give fosaprepitant (or other NK1 antagonist) for emetogenic prophylaxis when giving ifosfamide-containing regimens?
Related Questions
In platinum-refractory or multiply-relapsed NSGCT with 1–2 progressive sites and no good surgical option, is there a role for local radiotherapy (e.g., SBRT) to those sites?
How do you interpret nodes with minimal increased uptake on PSMA PET in prostate cancer?
How does the presence of indeterminate lymphadenopathy on PSMA PET scan alter your management of unfavorable intermediate-risk prostate cancer?
How do you differentiate between ERBB2 mutation vs HER2 overexpression testing when selecting patients for tumor-agnostic therapy?
How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?
Would the presence of only mature teratoma on orchiectomy specimen lead you to consider upfront RPLND followed by adjuvant chemotherapy as opposed to upfront chemotherapy in a patient with bulky para-aortic nodal disease (cN3) and AFP/beta-HCG elevation?
What is your preferred treatment for a patient with refractory metastatic upper tract urothelial carcinoma previously treated with adjuvant gemcitabine/cisplatin, enfortumab vedotin + pembrolizumab, docetaxel and sacituzumab govitecan?
Would you recommend enfortumab vedotin plus pembrolizumab for localized advanced non-invasive urothelial carcinoma of the renal pelvis?
How would you treat a patient with isolated CNS relapse of seminoma?
In what situations do you escalate the dose of Axitinib over 5 mg bid when administered with Pembrolizumab for clear cell RCC?
